Randomized double-blind placebo-controlled prospective, parallel, single centre clinical trial of bacterial vaccine (BACTEK) sublingual (oral mucosa) in patients with repeat bronchospasm for the immunomodulatory eficacy evaluation, security and clinical impact
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs MV 130 (Primary)
- Indications Bronchospasm
- Focus Registrational; Therapeutic Use
- Acronyms MV130
- Sponsors Inmunotek
- 22 Dec 2015 Planned End Date changed from 1 Nov 2016 to 1 May 2016, according to ClinicalTrials.gov record.
- 22 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 May 2016, according to ClinicalTrials.gov record.
- 22 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.